![conference banner](/images/conference-banner.jpeg)
Abstract
Topotecan and irinotecan (CPT-11) are both anticancer agents active in the inhibition of topoisomerase I, an enzyme involved in DNA replication and RNA transcription. During the last decades, an immense amount of research into this class of anticancer agents has been conducted, the positive results of which led to the clinical use of topotecan and CPT-11 in ovarian cancer and colorectal cancer, respectively. Here, we review the currently most important pharmacologic aspects of these drugs, including their mechanisms of action, metabolism, activity- and toxicity-profiles and mechanisms of resistance, to provide a global insight into their pharmacology. We also discuss the effects of combinations with other anticancer agents, which have been tested for synergistic antitumor effects. Pharmacokinetic and pharmacodynamic biomodulation, to enhance the bioavailability of the active anticancer agent or to reduce drug related toxicities have currently reached clinical application. As pharmacogenetics enters the clinical stage, this will lead to more “fine-tuning” in anticancer treatment (for instance by individualized dosing). The clarification of the mechanisms of action and resistance of topotecan and CPT-11 should enable us to understand their pharmacological behavior even better and might lead to the development of more potent camptothecinderivatives in the future.
Keywords: irinotecan, cpt-11, topotecan, topoisomerase I inhibitor, ovarian cancer, edorectal cancer, camptothecin
Current Cancer Drug Targets
Title: Pharmacology of Topoisomerase I Inhibitors Irinotecan (CPT-11) and Topotecan
Volume: 2 Issue: 2
Author(s): Ron H.J. Mathijssen, Walter J. Loos, Jaap Verweij and Alex Sparreboom
Affiliation:
Keywords: irinotecan, cpt-11, topotecan, topoisomerase I inhibitor, ovarian cancer, edorectal cancer, camptothecin
Abstract: Topotecan and irinotecan (CPT-11) are both anticancer agents active in the inhibition of topoisomerase I, an enzyme involved in DNA replication and RNA transcription. During the last decades, an immense amount of research into this class of anticancer agents has been conducted, the positive results of which led to the clinical use of topotecan and CPT-11 in ovarian cancer and colorectal cancer, respectively. Here, we review the currently most important pharmacologic aspects of these drugs, including their mechanisms of action, metabolism, activity- and toxicity-profiles and mechanisms of resistance, to provide a global insight into their pharmacology. We also discuss the effects of combinations with other anticancer agents, which have been tested for synergistic antitumor effects. Pharmacokinetic and pharmacodynamic biomodulation, to enhance the bioavailability of the active anticancer agent or to reduce drug related toxicities have currently reached clinical application. As pharmacogenetics enters the clinical stage, this will lead to more “fine-tuning” in anticancer treatment (for instance by individualized dosing). The clarification of the mechanisms of action and resistance of topotecan and CPT-11 should enable us to understand their pharmacological behavior even better and might lead to the development of more potent camptothecinderivatives in the future.
Export Options
About this article
Cite this article as:
Mathijssen H.J. Ron, Loos J. Walter, Verweij Jaap and Sparreboom Alex, Pharmacology of Topoisomerase I Inhibitors Irinotecan (CPT-11) and Topotecan, Current Cancer Drug Targets 2002; 2 (2) . https://dx.doi.org/10.2174/1568009023333890
DOI https://dx.doi.org/10.2174/1568009023333890 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Pathogenesis, Complications and Therapeutic Strategy for Hepatitis C Virus-associated Insulin Resistance in the Era of Anti-viral Treatment
Reviews on Recent Clinical Trials Green Tea Catechins as Novel Antitumor and Antiangiogenic Compounds
Current Medicinal Chemistry - Anti-Cancer Agents Identification of HnRNP Family as Prognostic Biomarkers in Five Major Types of Gastrointestinal Cancer
Current Gene Therapy Multifunctional Materials for Cancer Therapy: From Antitumoral Agents to Innovative Administration
Current Organic Chemistry Nanosized Modification Strategies for Improving the Antitumor Efficacy of MEK Inhibitors
Current Drug Targets Mechanisms Involved in the Protective Effects of Metformin Against Nonalcoholic Fatty Liver Disease
Current Medicinal Chemistry Discovery of MINC1, a GTPase-Activating Protein Small Molecule Inhibitor, Targeting MgcRacGAP
Combinatorial Chemistry & High Throughput Screening Activated Cancer Therapy Using Light and Ultrasound - A Case Series of Sonodynamic Photodynamic Therapy in 115 Patients Over a 4 Year Period
Current Drug Therapy Curcumin - A Novel Therapeutic Agent in the Prevention of Colorectal Cancer
Current Drug Metabolism Biologics: An Update and Challenge of Their Pharmacokinetics
Current Drug Metabolism Recent Advances in Developing K-Ras Plasma Membrane Localization Inhibitors
Current Topics in Medicinal Chemistry Anti-cancer Effects of a Neutral Triterpene Fraction from Ganoderma lucidum and its Active Constituents on SW620 Human Colorectal Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Artificial Intelligence Techniques for Colorectal Cancer Drug Metabolism: Ontologies and Complex Networks
Current Drug Metabolism The Regulation Role of Ferroptosis Mechanism of Anti-Cancer Drugs and Noncoding RNAs
Current Medicinal Chemistry High Therapeutic Potential for Systemic Delivery of a Liposomeconjugated Herpes Simplex Virus
Current Cancer Drug Targets Random Walks on Biomedical Networks
Current Proteomics Precise Analysis of the Autofluorescence Characteristics of Rat Colon Under UVA and Violet Light Excitation
Current Pharmaceutical Biotechnology An overview of ABC and SLC Drug Transporter Gene Regulation
Current Drug Metabolism How to Advise Aspirin Use in Patients Who Need NSAIDs
Current Pharmaceutical Design Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling
Current Drug Targets